In contrast, the methylation levels of the CpGs targeted in enhancer 3 (Figure 6b) and enhancer 4 (Figure 6c) were higher in the MGMT-expressing GBM samples than in the non-expressing GBM samples. The gene discussed is MGMT; the disease is glioblastoma.